SLP - Earnings call transcript Q2 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the Simulations Plus Second Quarter Fiscal 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. It is now my pleasure to introduce Alissa Fortuna from Financial Profiles. Ms.

Fortuna, you may now begin.

Unknown Attendee

Good afternoon, everyone. Plus Fiscal Simulations Conference Financial the Call. to Second XXXX Quarter Results Welcome are Executive of O'Connor, Frederick, me Shawn With today Chief Officer Chief Chief and Officer; Operating Plus. Officer Simulations Financial Will and

as we that remarks. earnings will today's our Please a note to updated supplement presentation, quarterly which serve prepared

website open You for the can Relations questions. access management's After on presentation www.simulations-plus.com. the call commentary, Investor our at we will

may Words include involve a believe, forward-looking assurances that can take As discussed actually reminder, refer that uncertainties. information be place. will include estimates this anticipate risks and today and best as like the expect -- no our call. these statements to that of There

is reports Commission. significantly the these could So our Exchange information results and Securities actual company's and statements. from future quarterly and in filed contained the risk with annual on differ factors Further the company's

the I'll said, now that With over turn Shawn? O'Connor. to Shawn call

Shawn O'Connor

everyone, second second conference you Alissa. thank for Good you, of fiscal our quarter Results afternoon, call. as XXXX played joining expected. Thank out XXXX and for fiscal quarter the

Our revenue share of strong growth of XX%, earnings Services both recorded Software in and $X.XX. performance solid our segments per team and with delivered diluted

year are first our results, Given our we we half meet will full strong guidance. confident

the full of from capabilities. Biotech market been benefit XXXX, in modeling first biotech have companies Our strong, that can strength. funding of of profile our especially encouraging to clinic. continues calendar and show candidates signs drug has the this In quarter of portfolio for simulation companies

market compared a on and outlook, drug stability companies, pharmaceutical business healthier their vary funding to overall near-term the large continues direction, ago. depending For to year but program is

optimistic modeling gain simulation of and will software and comprehensive for to conditions XXXX, our demand balance that the continue we market products services remain as improve. momentum cautiously For suite

I as development. performance, spend drug our of on topic relates our few to it and artificial Before turning intelligence a minutes segment to want to discovery

to tools technology technologies. early was optimize developer of As and previously, an Plus Simulations noted our I've AI predictive

enhance and keep use continue solutions. modeling our by AI technologies technology improving we to our develop, simulation As pace to of AI

only sets a AI data our accurate data the to is true edge business. and public entry for accuracy and Additionally, access as in training as to and competitive private barrier is our good a used

and and Our refining leaders us access private significant have partnerships This collaborations perfecting into data look critical with long-standing to digital regulatory advancing predictive economy, for and well agencies our algorithms. benefit and at stands evolving AI industry is to from data and applications. you science meaningfully broadly data, in capabilities both the access essential When to our the biosimulation AI-enabled to in rooted future. business granted public key both

to segment. our Moving Software on

are the increased revenues upsells quarter Software overall markets, solid our we period in with key XX% logo renewals, seeing up activity. X-month new Overall, market second and which in growth. were demand for except XX% lag Asia, the to for and good continued

Our revenue in Chem Informatics quarter fiscal XX% second business the unit for XX% and growth year-to-date. the delivered

ADMET was gain revenues added another quarter's biotech AI to This new Predictor, and adoption from which to growth due higher customer. continued

and customers new quarter. upsells during X were XX there the Additionally,

full GastroPlus upsells modest increase added unit Our year PBPK physiologically-based new quarter revenue for strong. had for and in pharmacokinetics X strong XX% are our unit customers second and The business expectations fiscal or Momentum growth a booked and PBPK year-to-date. existing the business X% X customers. is the for for

commit to Monolix to platform. the business revenue another from & strongest XX% or to the Pharmacology the fiscal large its performance primary take and transition and growth CPP pharma year-to-date. the delivered continues quarter Pharmacometrics unit, competitor share market XX% for of saw Our for Clinical with client

added had customer X we customers XX During and the quarter, new upsells.

XX% or Quantitative Pharmacology for quarter X% increased for and unit Revenue decreased the year-to-date. QSP business our Systems the in fiscal

be can for results and lumpy high a end As of based a users. per on QSP small quarterly license pool price reminder,

the XX% being RFs, Services and cautious segment. but with scientific volatility start increased lingering we're through well second are drug seeing stop about trials, pickup and decisions X-month delivery spending, the project and pipeline is are and our data flow still to a on to during staff. associated sign. activities quarter volatility disruptions of XX% Revenues Turning solid clinical which but a period in active Clients healthy positive steady bookings the of for completion opportunities. a we of quite a programs related to utilization maintain with managing and of our this There's

which year. of Services the is impact million, second for strong XX% XX% our in were fiscal quarter and revenue up of solid, the was full the half enter backlog of $XX the unit we second the year CPP in Total despite as end the quarter second at fiscal our volatility. business

projects. after unit, grew XX% and In and increased Services our unit business performance. benefiting in second full quarter the growth quarter for fiscal a for year, our in second QSP delivering XX% the the sluggish first business model quarter year, and from immunology service revenues revenue for XX% PBPK strong XX% fiscal cancer the full

over And with Will. that, I'll turn to the call

William Frederick

our you, revenue quarter performance, total Thank recap strong increased $XX.X million. second To XX% Shawn. to

a XX% revenue revenue increased revenue Software services and XX%, and XX%. services trailing increased total revenue XX-month increased basis, representing increased revenue XX% On of XX%. software

first performance our customers quarter, business providing on improve improved last our focus operational and in implemented unit while with us investors continuing improve to allowed structure we on to departmental focus our the visibility also progress. to a our to the communicated profitability quarter we reorganization As evaluate

gross our periods. no revenue departments. does a compared all has cost impact impact the we to prior moved As margin income, result, into through services trend services but personnel on net total cost of This

year XX% of Approximately million decrease at the expenses. to software gross was increase compared XX% in $X.X margin XX% with XX%. XX% of margin corresponds total margin cost QX to last G&A million Accordingly, services versus a XX% versus revenues gross at in and $X.X

quarter. QSP X%. XX% was the unit by Turning XX%, for CPP ], was XX% business [ PBPK to was software and was revenue Cheminformatics contribution

PBPK XX%, XX X%. months, CPP XX%, was was trailing the was was contribution and Cheminformatics XX% QSP For

and For the increased accounts. trailing to XX on based renewal based increased fees XX% XX% customer on months, our rate to

For the trailing increased customer revenue per months, XX to average $XX,XXX.

to was services our XX%, CPP unit PBPK XX% was XX%, X%. was for business QSP was by contribution the revenue REG Shifting and quarter,

CPP XX to XX%, approximately increased XX Anticipated XXX, to and XXX trailing backlog on year, worked XX%, services QSP was $XX.X was from -- months, X%. projects to the contribution PBPK million million the decrease was REG last was quarter For months end revenue backlog within compared last and XX% increased $XX quarter from Total year. was a slight during

X% X% compared last year; compared R&D XX% was G&A marketing Turning income XX% to year; to to sales revenue was of year. to before revenue our consolidated XX% and and were of income revenue last revenue, income revenue year. XX% quarter. Total was income XX% compared was as XX% statement from for to last revenue and of XX% the compared expense last of year; XX% expenses expense XX% of expense last of to operations compared operating taxes year; was last same

partially by of $X.X to earn-out due primarily million, for fair year, an Year-over-year and of in expenses adjustment in acquisition stock primarily was to the $X.X of $X.X this quarter the increase increases increase million. income additions, an liability salary last were million annual million due income due to compensation headcount employees. $X value Other to existing adjustments offset increases Immunetrics, general in the increases of interest compared compensation-related Immunetrics

a year's the reflecting XX% was year compared XX% last for revenue million income earnings share shares decrease revenue as as last a of repurchase. $X to of share same Net quarter or last $X.XX, at Diluted diluted outstanding second million the per of result $X.X year. or was in

related and financial adjusted back any or metric and our $X.X relevant were or of of stock-based impairment to and exchange, interest, year, EBITDA non-GAAP charges asset provisions taxes, depreciation to quarter expenses, tax amortization, million website. compensation, our increased revenue. these net The this EBITDA adding in gain million acquisition compared calculate to the any XX% on $X.X reconciliation on We Second by GAAP metric earnings release benefits items. transaction-related adjusted is income to or loss and currency last any both

was The the changes tax million was and taxes last we year, foreign XX% estimated primarily compared differences expense prior tax-related to in second of to result million the tax for our and $X.X benefited increased rate Income increased year rate from year. quarter last effective tax year. last $X.X XX%

the Now for year that rate we're halfway XX% through XX%. to tax full our fiscal estimate fiscal year, current our effective is

development to initiative to turning to as balance acquisitions, our the corporate continue in with allocation remain investments We $XXX.X million Finally, sheet. partnerships. quarter investments. we We for cash and and strategy our strategic opportunities seek capital ended committed and

the turn now Shawn. to back I'll call

Shawn O'Connor

you, Thank Will.

which We share targets, revenue. performance, $X.XX total to between XX% XX%. require $X.XX well guidance quarter cautiously results bookings to market growth improved, million Services and with both they the revenue but improvement, XX%, first translate $XX actual of and XX%, between and mix million, XXXX into include: half growth in services XX% second meet reflected Software stated of strong between per strong $XX mix earnings software segments. With have optimistic. XX% and conditions of Market are and in share changes our and performance our range we year-over-year before XX%, earnings XX% diluted time revenue these per year-over-year Our our to diluted to combined positioned fiscal remain

consulting We're technology and of to Before drug regulatory to a in and services biosimulation discovery take tools I'd story. large is growing the market. to company's to the the through and opportunity Q&A, AI beyond a inception leader biosimulation turning differentiators like Simulations leveraging development in software clear leader to a reinforce Plus approval. clinical since in optimize key and our

customer high We compelling entry. strong barriers have position and a to with value competitive proposition

a team turn finally, and an call expertise for operator for we time today. And in attractive and questions. simulation. Thank a you with the We over have debt. to And seasoned leadership I'll with scientific that, modeling sheet the have strong management no balance your significant profile with and financial

Operator

question the first Hewitt of from Craig-Hallum. line Instructions] Matt [Operator Our comes with

Matthew Hewitt

good macro second to quarter on up some row. follow environment. the a on on starting biotech bit to here see little the you're side. Congratulations Obviously, Maybe a the improvement in first

some side, that. the there funding a pharma the kind large on some funding the and maybe versus other that items You commented hit is the it on reprioritization of pharma that? past on of kind market quarters? of that I'm large just as side of is much Is over of few how more that some well? Or wondering, have the

Shawn O'Connor

Thanks, Matt.

their new acquisition, streams, created a couple years, different, last a side. less biotech funding the on pharma been has related have the side, I there. to resorting should circumstances been in outlook programs, it's turn their issue terms Pharma exposure access of of certainly the and On has of their funding versus programs investments environment individual been little patent company, it there, on the or revenue say, biotechs During as

a Nordisk of Novo got announced extreme Pfizer as this other year. and range wide scenarios example at You've companies cutbacks from an one that's get significant

of there's has is been most in in X funding to lot and in streams. companies into between of So out in. everyone of issue still But churn invested drug of programs sorting their invested cautiousness those terms that and are obviously an situation. be not those less Capital or going a

Matthew Hewitt

Got that start your it. is when is there does strong lag? the is in been think X year. bookings or Or And secondary -- a bit it quarter So quickly I seeing seeing how then of hit, pretty regarding historically? everyone's mean, in biotech a the funding, you I see away? there obviously, the that show But has lag quickly? to right a start to a from the Or revenues the it IPOs up do kind perspective? little of we're

Shawn O'Connor

seat need Yes, terms mean in those on it's are we'll are anecdotal drug drug our just when it I candidates where development. tomorrow. their activity. of sales I range get depending I they to a cycles I funding, to new need budgetary the in industry of can cycle somebody candidates prolonged -- the hired where see. Typical and

terms sort thereabouts funding of it's an -- X-month, answer or the to I'm of So within can't across of your question cross activity. a it's I know timing. to X-month first quarter spectrum But give dancing the a certainly, -- runs lag around you in because I

would are are getting to especially anticipate You're drugs be market the the funded to the of going not the companies to a their that of X- are quick close those volume. But range, these drive in looking clinical I advancing decision that turn to are see go to going decisions. terms many in in candidates, with X-month next level, that protocol those next trial, points funding their clinic, in purchasing getting

Matthew Hewitt

in the were of in last hop Got wins, big customers Maybe drove what last the up I Xx me, maybe it. versus ADMET, the say, obviously, more And should there. number pop bit the pop then a back I on your more think little for upsells quarter. queue. and new quadrupled quarter, versus one a color But I'll you strong

Shawn O'Connor

or there, many of is focused ADMET on supplement contributions The Predictor in that acceptance the are building space marketplace the the company technology market. technologies what extremely are make they pleased were in new brought licensed separately. start-up that those AI the that, in not we new yet terms we're another which Yes. solutions, is what companies The AI just and recognition questions the doing. more by to to our biotech I'm getting being Predictor of ADMET tool and generative very

of many value continue and brought optimization what AI endorses think these to the replaced improve and being process. enhance that to in for the technology and lead many built or build years the and here market place technology of terms that we've we're and hazards not of I builds value displaced in

Operator

Our of David the next from question Larsen comes BTIG. line with

David Larsen

Congrats that it very looked quarter. on a given harmonization the good last especially had very to increase you you bit Can about sequential the process a I in little revenue. GastroPlus year. talk mean me, good

be more that any or color would Just thoughts around great.

Shawn O'Connor

Yes. quarter tremendous, different last the was this quarter was harmonization as but that step-up the Growth bit motion here year a pattern year-over-year in the in comparison little completed seasonality set our specific to year. process not

jump process closure was doesn't And not. performing what that end the their an mean First there larger sequentially complete, to GastroPlus Harmonization to given that second slip quarter quarter based the one quarter licenses quarter from well. upon us. another quite aren't quarter for jump and even of at

to China, that. some prepared had of the from taking in comments in we Referenced terms in Asian spending some seeing, place regard the especially we're in issues pullback so well-known where related And market, to with there. impact softness

and momentum expectations revenues. for a overall look at to very our the to So good performing to that is year, our in grow pace on GastroPlus. continue We're for steady to

David Larsen

is then IQVIA mean research I growth. that clinical or virtual they've I best like second increase clinical was to activity. And of showed tied Monolix. year-over-year I mean huge increase is think It quarters I IQVIA. the over in for think, create their it there retook there ever I'm very Can't [ -- Okay. I one is third was, guess, in good tremendous drove XX% how seeing printed, And the business, maybe a there correlation best it any that? trial like Monolix XX% what trials? growth? Or year-over-year, ] year-over-year they

Shawn O'Connor

product had needs to few the the in doing use yet go has it competitive well, product and leading the nice Monolix the harmonization fast their since continues its marketplace, entirely our displacing quarter, we made software there. that through a pharma these to to company fastest-growing that grower, for the commitment of Monolix of incumbent, Yes. product. our is last process the acquisition made past another market platform, line displace and XXXX This quite last share years large year, in been perform XXX%

So future. into momentum and progress strong the continues quite

is that therefore, that being it's clients to trial But indirect trials It's on But direct tied to immediate strong copy and and staff got Monolix is so leads trials quarter. activity. Yes, We generally, hey, and growing our not quite the need clinical that, not clinical we've performed. correlation clinical a Monolix. this amount modeling quite quarter-to-quarter. an simulation XX programs, of of extra between development there And so need

David Larsen

in mean, it looked it $XX,XXX that that's in mean, though, I XQ. from in at average me. revenue Okay. down to you XX%, very a customer, retention up $XXX,XXX, The fee like but I was the I then And XQ. think great good came had from per the pricing, XXX% quarter,

Just sort on that? What's anything of going there? driving

Shawn O'Connor

typically mid-XXs terms Yes. XX, of a XX at we've more operated level, in fees.

extraordinary. performance quarter Our was quite last

it, I even about norm I out compared the which that peak I'm kind will rate, the complained a not QX. was quarter be as of this be And should so though, of so say, slipped always revenue to couple renewals there -- were it of mentioned, to created a complaining we but for renewal

shape So of the the accounts there. of renewing The are price I implemented. think deal, stickiness our we're in increase as the components that good number

those performing of at All point. this be well seem to

David Larsen

of revenue then you investments And my it's of Is yet? recently effort. enable great. Great. this pharma talk made them may actually would successful with new be you Okay. some announced any significant corporate how help any some launch potentially that Just if a could a development understanding you long is? a that about Can just little you upside, that capture you drug, maybe the bit you to color capture client that term. works? and you And Have it a work stream there very what

Shawn O'Connor

opposed acquisition them benefit existing and road. that the from technology, get all candidates the reasons at capabilities, whole very for some Yes, foremost have might capital technology, terms to built Plus number speak of may number not a but an of this our terms at looking Dave. technological that year a of companies quickly mature strategies, a Yes, host they've program stage we Simulations #X service we more out things portfolio. encounter priority their which add technology and in the the in first and of identifying become additional positive go-to-market as as down for here. the to But strategy, acquisition was And remains this really down in into the use situations the target our game. borne to have that It acquisitions to product linkage be and that of opportunities we integration of of could acquisition certainly our of of yet effort, waiting

one being investment those of are as number speak hope companies, these of we companies success investments that Yes, assessed would of nature. to their use maybe a opportunities find charge then in our include us some drug which candidates the and mean investments drug their this to make in to of mission So allow well. maybe I first of processes development technology, our programs our and by they're as play profile

interesting there foremost present it we and terms benefit technology might will and license be software the term. in of development filter revenue revenue, business sort their first drug success in our from its an but service long where and/or of Our be program model, able be which their would scenario to value does

Operator

Next line with question comes from the Brisebois François of Oppenheimer.

FranÃ§ois Brisebois

been just was and there misunderstanding drug accelerate bit algorithms product? you the data in and in that while shorten that of differentiates always a could from on strong development of guys to has plays? you is time anyone for evolved, terms to newer be very going wondering, been has I -- of build you have a And the you maybe data little getting data, business? is of path AI that have around else that guys a of guys to the these what have kind that on or based is edge an just but something been kind to Or for you

Shawn O'Connor

generation here we some and that which get the ventures other Predictor we've our use typically the there funding. focused so purpose. very that Frank. with for participated in -- biomarker ventures in always its spotlight out And that the have we some in that impact question our product And and Good the attention of the The some of the identification, in think areas, is nature. best-of-class questioned AI new marketplace and prediction. product mean, development technology of of of technology funding for of question, time received property great garnered AI technology abound. focused one perspective is I And got have terms terms in are in ADMET lead ourselves

property development, other before, in fact our and them mentioned in prediction I'm doing and of what displaced endorsing this quite supplement technology best-in-class investments tool I we became as our that the by one quarter, perspective is we're best customer yet that a are another using of breed that pleased developing. And these being are they're what

context of focused and the certainly, use have comfortable feel our and with position in have yes, technology. success AI, we So in our we'll of the that

time. your but terms obviously the volume for second of terms as tremendously, as been data both Public and still extended its the a data improved data, we've are public far has obvious its of in an of period part challenge. in question, the and accessibility, curation sources. of game is In private The

years of to a into do. terms got work that in rating means meaningful we that used can curate developing that of we've of the So a edge data format in a be terms

and readily partnerships, always curation. On our working to have data that where advantage and of side, our regard, others others got into running is the to the of or on allowed there ahead agencies data need hard stay to private I of improve to access in of capability collaborative in in with there. ongoing anyone, believe terms with again, and/or that not our keeping There data to do years come curve partnerships can predictive this back we've stay clients us is of ability evidence a capability out the can Predictor regulatory And we part that. apply we make have available ADMET terms in that

FranÃ§ois Brisebois

actually them these you the of help get acquisitions it's to are if notes. to compare talked pharma as of large much the help using biotech if for well maybe been program my of pencliffs so they're revenue -- biotechs. of at large large biotech, software it just lot pharma would growth much looking so and of these selling the biotech just a from coming do the when kind and questions I'm generation with the And them in was previous bit of about if comes because wondering versus in from little here, of a biotech, lastly, terms terms then but ever pharma,

with here? ever biotech that has where Or large separate helps pieces So out really, are pharma really happened clients? they

Shawn O'Connor

relationship. into large We've of not a searching result and example strongarmed biotech for an I'm Frank. introduced a separate pharma a the piece, been it's as never where

of in occasionally no, targets Our may some there. their internally could pharma that out great it's get used I -- of frequency. opportunities, investment process diligence assessing and in being at know in but We involved not acquisition due a be don't their assessment large that happening But evaluating tools be lot the to They a leverage talking product pharma about and companies. biotech hire from look an to they into that there's of impact people, hire goes of that the terms biggest SLP quickly creates sales we probably were funding cycles as users, pre-existing is people opportunity large more in are earlier.

sales to In that leads funding undertake there as cycles biotech. the really probably of of filling in as a biotech hiring terms new and of funded individual to their our efforts in leading is to an on tool between his hiring kit knock acquisition, to internally an door then terms a

FranÃ§ois Brisebois

could you your the if actually Or this good But squeeze programs don't have did to distant the all far is impact is cut future software start expect cost see of with success. Do this you like for you was here, a costs? future of at cut too one you starting the one I with guess? happen the necessarily see definitely makes really and lower do this long turn, to go sense. further to a not your that is funding that And Ultimately, chance was thesis if because in last big to just year. it's funding I ultimately, the guys do with the ever tough biotech No, advantages is in. time -- and of

Shawn O'Connor

long removed know in Hopefully between the be far there still steps programs. there. the little But more certainly of The linkage you improves programs, terms funding in it's you're bit, in lead that I couple -- on getting ratio describing. you're lead the efficient think any run, their I in and help provide that and a a efficiency of we'll columns future to can successful don't can know out biotechs those static the pretty it's predicting funding. we don't somewhat that take or less of guard I think I funding remaining that -- Yes, spreadsheet the will

FranÃ§ois Brisebois

maybe thing I Yes. like environment, meant dependent for of on downturns the whatnot. just less future, funding or sort

Shawn O'Connor

a place, of on entity we on in efficient more even the takes may more -- efficient spend efficient may No, we may for on have further impact that can development. spend to more drug depending program funding terms or funding spend certainly the that. that circumstances But of not and require the lead

Operator

question from follow-up the a is question David line Larsen. of next Our

David Larsen

Will of think, role, about to his a question wanted of I I Operating new ask sort Chief expanded Officer.

-- Will, that And color seeing up you can do that? COGS. from little Just some of into what a Why are costs you talk G&A very Just about would reclassification you did maybe any the bit perspective? be helpful.

William Frederick

Sure. to Happy do that.

we're I think services organization the that our software a the do us it at running to like the one as operations things definitely way of allowed company is entire -- and operations operations.

most focus, or sales more mentioned, in and way we sales a step revenue. our costing throughout costs marketing, of did reclass that spend. further of that we in to the I'll percentage acquisitions, our best this we've Certainly, have ones to in impact company I on drives that addition total recent synergies, the What's the call us, practices and we've what's to a to spend as a and this incorporate tried services improve and into But were that development, allocations marketing was G&A more on, clarity, at of So percentage rates the reported sales and as consolidation. give year, what's no as one looking them. done organization, it, always we've our we progressed one the marketing little our effort tried organization really the utilization we've where can since bit revenue a cost script our as and leverages

focus company leverage M&A. out most drive the on have of helping I business. we importantly, really focus So can a future to that the profitability, on future mean, areas the get continue And we

in companies should us that nice keep and new synergies to on infrastructure hopefully layering some allows this the in that infrastructure place future. bring having So in us allow to see

David Larsen

organization, just little have at FTEs How are in carrying? Sales better organization? like integrations of that's and in a was there what? per color there earnings many just you Or individual just recently? many you one. I quite Can heard integrated helpful. say the obviously other would who you be were quota Immunetrics? the happened was you then talk each in then How into a do that very integration it And of frankly. Just about And last I had important. your sales hear, look what to What any Fantastic. exactly department Was sales? sort you is sales mentioned force, bit

William Frederick

that you want you Do to going? let me Do want take Shawn? keep one, to Sure.

Shawn O'Connor

it. go You for

William Frederick

right. All

So the constraints have Immunetrics in we are can it, sales earn-out, within direction existing certainly, with strides so there leverage made fully do we acquisition, an we've to force. but integrate where certain our

where amount You've to the have that talk the services, the units different leverage customers We sales still heard that work the can sell organization, of higher marketing within about from decision-makers. we software we continue business to value up same us got about cross-selling, chain and folks.

quarter or a Chief So marketing. And Revenue salespeople want carrying say, Dan in just great certainly this about Officer. X Zout quota addition are with that there's Shawn, about I recently last to our XX X as

Shawn O'Connor

presentation our clients consolidating them and create as together from before was and a resources started it into time company. at good. more efficiencies. some acquisitions, that at marketing one previous a process sounds of focus in sales go-to-market Immunetrics years our internally the one of importantly, consolidation terms the pulling really to time, divisions ago. It And the couple The organization of was But

a our and All across existing support customers. to that's accruing while. across and here to cross-selling platforms upsells benefits leads to think been And I that of for services

Operator

remarks. the There are I'd Mr. like for queue. back no it closing in O'Connor hand to to questions further

Shawn O'Connor

everyone's appreciate to soon. Take good. and I on all I attention care today is well Very forward speaking hope your look again and all. side Well,

Operator

gentlemen, conclude your you and Ladies teleconference. participation. this today's does Thank for

You may disconnect your and lines at this a day. wonderful have time,

Simulations Plus (SLP) 3 Apr 242024 Q2 Earnings call transcript